SG11201808246SA - Methods for treating and preventing c. difficile infection - Google Patents

Methods for treating and preventing c. difficile infection

Info

Publication number
SG11201808246SA
SG11201808246SA SG11201808246SA SG11201808246SA SG11201808246SA SG 11201808246S A SG11201808246S A SG 11201808246SA SG 11201808246S A SG11201808246S A SG 11201808246SA SG 11201808246S A SG11201808246S A SG 11201808246SA SG 11201808246S A SG11201808246S A SG 11201808246SA
Authority
SG
Singapore
Prior art keywords
treating
preventing
methods
difficile infection
difficile
Prior art date
Application number
SG11201808246SA
Other languages
English (en)
Inventor
S Tanaka
Michael Draper
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of SG11201808246SA publication Critical patent/SG11201808246SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11201808246SA 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection SG11201808246SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US201662320053P 2016-04-08 2016-04-08
PCT/US2017/023958 WO2017165729A1 (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Publications (1)

Publication Number Publication Date
SG11201808246SA true SG11201808246SA (en) 2018-10-30

Family

ID=59900751

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201808246SA SG11201808246SA (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection
SG10201913559VA SG10201913559VA (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913559VA SG10201913559VA (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Country Status (13)

Country Link
US (3) US20170319603A1 (enrdf_load_stackoverflow)
EP (1) EP3432891A4 (enrdf_load_stackoverflow)
JP (3) JP7458706B2 (enrdf_load_stackoverflow)
CN (2) CN109152789A (enrdf_load_stackoverflow)
AU (3) AU2017238644B2 (enrdf_load_stackoverflow)
BR (2) BR122024000249A2 (enrdf_load_stackoverflow)
CA (1) CA3018872A1 (enrdf_load_stackoverflow)
MX (2) MX2018011413A (enrdf_load_stackoverflow)
MY (1) MY197627A (enrdf_load_stackoverflow)
PH (1) PH12018502020A1 (enrdf_load_stackoverflow)
RU (1) RU2751509C1 (enrdf_load_stackoverflow)
SG (2) SG11201808246SA (enrdf_load_stackoverflow)
WO (1) WO2017165729A1 (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152789A (zh) * 2016-03-24 2019-01-04 帕拉特克药品公司 用于治疗和预防艰难梭菌感染的方法
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
SG11201903846TA (en) 2016-11-01 2019-05-30 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
KR20210090160A (ko) * 2018-09-04 2021-07-19 파라테크 파마슈티컬스, 인크. 테트라시클린 화합물을 사용하여 미코박테리아 감염을 치료하는 방법
KR102837762B1 (ko) * 2018-10-10 2025-07-23 누트리 컴퍼니 리미티드 클로스트리디움 디피실균 감염증의 예방 및/또는 치료제
JP2023530415A (ja) * 2020-06-11 2023-07-18 パラテック ファーマシューティカルズ，インコーポレイテッド オマダサイクリンの結晶形態、その合成方法及びその使用方法
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001818A1 (en) * 1991-07-24 1993-02-04 The Procter & Gamble Company Antimicrobial treatment methods and compositions
CZ303702B6 (cs) * 2000-07-07 2013-03-20 Trustees Of Tufts College Minocyklinové slouceniny
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP1408987B1 (en) * 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
JP2009521456A (ja) * 2005-12-22 2009-06-04 ワイス チゲサイクリンでの胃腸管感染症の治療法
US9078811B2 (en) * 2006-01-24 2015-07-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
TW202021946A (zh) * 2008-05-19 2020-06-16 美商派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
WO2010093776A1 (en) * 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
EP2558493B1 (en) * 2010-04-15 2019-09-18 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of clostridium difficile-associated infection and disease
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2014121302A2 (en) * 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
CN109152789A (zh) * 2016-03-24 2019-01-04 帕拉特克药品公司 用于治疗和预防艰难梭菌感染的方法

Also Published As

Publication number Publication date
SG10201913559VA (en) 2020-02-27
JP7458706B2 (ja) 2024-04-01
CA3018872A1 (en) 2017-09-28
MY197627A (en) 2023-06-29
JP2022115985A (ja) 2022-08-09
MX2018011413A (es) 2019-01-10
JP2024023187A (ja) 2024-02-21
CN109152789A (zh) 2019-01-04
RU2751509C1 (ru) 2021-07-14
JP2019509318A (ja) 2019-04-04
AU2023200798A1 (en) 2023-03-09
AU2025202020A1 (en) 2025-04-10
EP3432891A4 (en) 2019-10-30
US20200281948A1 (en) 2020-09-10
AU2017238644A1 (en) 2018-10-25
CN119454720A (zh) 2025-02-18
PH12018502020A1 (en) 2019-07-15
US20170319603A1 (en) 2017-11-09
US20250049819A1 (en) 2025-02-13
MX2023004969A (es) 2023-05-24
BR122024000249A2 (pt) 2024-02-27
AU2017238644B2 (en) 2022-12-15
BR112018069303A2 (pt) 2019-01-22
WO2017165729A1 (en) 2017-09-28
EP3432891A1 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
IL283779A (en) Systems and methods for preventing, alleviating and/or treating dementia
SG11201808246SA (en) Methods for treating and preventing c. difficile infection
IL269371A (en) Treatment methods
IL274040A (en) Methods for treating hepatitis B infection
IL254596A0 (en) A method for operating a reverse osmosis membrane treatment system and a reverse osmosis membrane treatment system
EP3107642A4 (en) Systems and methods for treating blood
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
GB201608885D0 (en) Treatment
IL271728A (en) Materials, uses and treatment methods
IL252197A0 (en) A method for treating, preventing or reducing the risk of skin infection
IL291266A (en) Preparations and methods for treating infections
ZA201907283B (en) Compositions, devices and methods for treating autism
EP3537972C0 (en) CHEMICAL-PHYSICAL SYSTEM FOR THE TREATMENT OF TINNITUS
EP3283103A4 (en) Methods for treating clostridium difficile infection and associated disease
GB201402909D0 (en) Treating infection
EP3302684A4 (en) METHOD AND DEVICES FOR TREATING THE CORNEA
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
ZA201904328B (en) Composition, application thereof and treatment method
PL3481194T3 (pl) Wodne kompozycje do zaprawiania nasion, zaprawione nimi nasiona i sposoby zaprawiania nasion
EP3258958A4 (en) Compositions and methods for preventing and treating rhinovirus infections
HK40003650A (en) Methods for treating and preventing c. difficile infection
EP3490369A4 (en) WATER TANK FOR DOMESTIC ANIMALS, TREATMENT AND RELATED METHODS
HK1262014A1 (en) Methods for preventing and treating pneumocystis infections
IL252399A0 (en) Systems and methods for water repellent treatment in protective fabrics, and protective fabrics produced using them
HK1252692A1 (zh) 治疗或者预防蛋白质构象病的方法